What reasons can cause a trial to unexpectedly go away? What happens when it does? In today's episode of Riding In Cars with Researchers, Jeff Kingsley outlines some scenarios that would cause trials to suddenly close or never reach start-up despite preparation, and gives some practical suggestions for how #clinicaltrial sites can prepare for this in the future. 

What is appropriate clinical trial site budgeting? How can sites go about improving their budget negotiations? Today, Dr. Jeff Kingsley outlines the steps to take in order for your site to budget for trials successfully.

A full transcript of this podcast can be found on our blog:
https://iacthealth.com/riding-in-cars-with-researchers/ 

Follow Us On: 

Instagram: https://www.instagram.com/centricityusa/
Facebook: https://www.facebook.com/centricityusa
Twitter: https://twitter.com/CentricityCR
LinkedIn: https://www.linkedin.com/company/centricityresearch/  

Contact Us:  
Messenger: m.me/CentricityUSA  
Phone: 888-737-7408 

What is the right size of a clinical research site? Small or large? Today, Dr. Jeff Kingsley gives insight into why he believes one site size prevails over the other.

A full transcript of this podcast can be found on our blog: https://iacthealth.com/riding-in-cars-with-researchers/

Follow Us On: 
Instagram: https://www.instagram.com/centricityusa/
Facebook: https://www.facebook.com/centricityusa
Twitter: https://twitter.com/CentricityCR
LinkedIn: https://www.linkedin.com/company/centricityresearch/  

Contact Us:  
Messenger: m.me/CentricityUSA  
Phone: 888-737-7408 

How do you choose which research trials you should or should not be conducting as a research site?  Dr. Kingsley speaks to sites, business development professionals, and other key decision makers about the 3 things you should consider: the greater good, business development, and business in general.

When considering a trial for your site to conduct, you have to assess both people and site capacity.  If you are not measuring your site’s capacity, it will affect your site’s performance and may lead to failures.  Find out more in this week’s edition of Riding in Cars with Researchers.

Let’s talk about the differences in the use of pandemic, endemic, and epidemic and how we use them.  Is COVID-19 considered a pandemic?  Find out in this week’s episode of Riding in Cars with Researchers.

In an interview with Dr. Joseph Surber, Chief Medical Officer at IACT Health, Dr. Jeff Kingsley gets to the heart of the importance of both physicians and patients participating in clinical research trials.  For physicians, isn't that why you got into the medical field - to make medicine and the lives of your patients better?  For patients, participating in clinical research trials gives you an option to participate in a modality that you would otherwise not have access to as well as it being free!  

Learn more about the benefits of clinical trial participation for both physicians and patients! 

Do you know where to spend your marketing dollars in Clinical Research? How do you decide what areas to focus on? What percentage of your budget should go to what medium? How to implement your strategy?

In this special edition of Riding in Cars with Researchers, Dr. Jeff Kingsley has a conversation with Dr. Christine Senn, Chief Strategist of Research Designed and COO of IACT Health, where they discuss ways to improve your existing marketing, tips to help attract patients, and how to maximize your marketing impact.

The use of technology in research is potentially of immense benefit.  Research requires a ton of attention to detail and it is easy to make a mistake when you are using paper or paper source documents like eSource.  The use of smart technology would make that easier and enhance data integrity.  Look into different technology and test them:  plan, do, act, and study!  Did it work?  Technology will revolutionize research and enhance the quality coming out of clinical research sites.  

There has been a movement going on for 28 years now to move research into the patient's home making it easier for patients to participate in research. The hardest thing we do is find patients who can meet the stringent criteria for research, and who have the time and the willingness to participate. If it’s the hardest thing we do, we need to remove as many barriers as possible, and make it as easy as possible for patients to be able to participate. The direct-to-patient movement is aimed at that.